Goldman Sachs Assumes Coverage on FibroGen (FGEN) at Neutral
Tweet
Share
E-mail
Get Alerts FGEN Hot Sheet
Price: $9.71 --0%
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi assumes coverage on FibroGen (NASDAQ: FGEN) with a Neutral rating and a price target of $45.00.
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $35.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
